```
ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS
L17
AN
     1999:511185 HCAPLUS
DN
     131:156910
     Three-dimensional structures and models of Fc receptors and uses thereof
ΤI
     Hogarth, P. Mark; Powell, Maree S.; McKenzie, Ian F. C.; Maxwell, Kelly
     F.; Garrett, Thomas P. J.; Epa, Vidana; Baell, Jonathan
     B. { Matthews) Barry R.; McCarthy, Thomas D.; Pietersz, Geoffrey A.
     Ilexus Pty. Limited, Australia
     PCT Int. Appl., 327 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LA
FAN.CNT 1
                         KIND DATE
                                                APPLICATION NO.
     PATENT NO.
                                                                     DATE
                         ____
                                19990812
                                                 WO 1999-IB367
                                                                      19990204
     WO 9940117
                         Α1
PΙ
          W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
          DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, CN, CM, MI, MB, NE, SN, TD, TC
              CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
60 AA 19990812 CA 1999-2
                                                 CA 1999-2316860 19990204
     CA 2316860
                          A1 19990823
     AU 9924382
                                                 AU 1999-24382
                                                                     19990204
     BR 9907964
                                20001017
                                                 BR 1999-7964
                          Α
                                                                      19990204
                                                 EP 1999-903878
                                20001122
                                                                     19990204
     EP 1053255
                          Α1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                                20001004
     NO 2000003964
                                                 NO 2000-3964
                                                                      20000804
PRAI US 1998-73972P
                          Ρ
                                19980206
                              ( 1998091b
     US 1998-99994P
     WO 1999-IB367
                          W
                                19990204
     Disclosed are crystals, crystal structure Fc.gamma.RIIa protein,
AB
     three-dimensional coordinates of Fc.gamma.RIIa protein, and structures and
     models derived from the Fc.gamma.RIIa structure. Also disclosed are
     crystals of Fc<eRI protein and three-dimensional coordinates of
     Fc.epsilon.RI protein monomers and dimers derived from the Fc.gamma.RIIa
     structure. Also disclosed are three-dimensional coordinates of
     Fc.gamma.RIIIb proteins and models of Fc.gamma.RIIIb derived from the
     Fc.gamma.RIIa structure. The present invention also includes methods to
     produce such crystals, crystal structures and models. Uses of such
     crystals, crystal structures and models are also disclosed, including
     structure based drug design and therapeutic compns. for IgG-mediated
     tissue damage, hypersensitivity and inflammation.
     131597-43-8 155360-69-3 237072-16-1,
     Fc.gamma.RIIa receptor (human) 237072-19-4, Fc.gamma.RIIb
     receptor (human) 237072-22-9, Fc.gamma.RIIc receptor (human)
     237072-24-1, Fc.gamma.RI receptor (human) 237072-26-3
     237072-29-6 237072-33-2 237072-41-2,
     Fc.gamma.RIII receptor (human clone seg8)
     RL: PRP (Properties)
         (amino acid sequence; three-dimensional structures and models of Fc
         receptors for drug design for treating IgG-mediated tissue damage,
         hypersensitivity and inflammation)
```

- RN 131597-43-8 HCAPLUS
- CN Receptor, immunoglobulin A (human clone pHuFc.alpha.R precursor protein moiety reduced) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 155360-69-3 HCAPLUS
- CN Fc.epsilon.RI receptor (human clone p1-p26 subunit .alpha. reduced) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-16-1 HCAPLUS
- CN Fc.gamma.RIIa receptor (human) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-19-4 HCAPLUS
- CN Fc.gamma.RIIb receptor (human) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-22-9 HCAPLUS
- CN Fc.gamma.RIIc receptor (human) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-24-1 HCAPLUS
- CN Fc.gamma.RI receptor (human) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-26-3 HCAPLUS
- CN Fc.gamma.RIIa receptor [27-glutamine,131-arginine] (human) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-29-6 HCAPLUS
- CN Fc.gamma.RIIa receptor [27-tryptophan,131-histidine] (human) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-33-2 HCAPLUS
- CN Fc.gamma.RIIa receptor [27-tryptophan,131-arginine] (human) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- RN 237072-41-2 HCAPLUS
- CN Fc.gamma.RIII receptor (human clone seq8) (9CI) (CA INDEX NAME)
- *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
- IT 64-19-7, Acetic acid, biological studies
 RL: ARU (Analytical role, unclassified); BSU (Biological study,
 unclassified); ANST (Analytical study); BIOL (Biological study)
 (buffer; three-dimensional structures and models of Fc receptors for
 drug design for treating IgG-mediated tissue damage, hypersensitivity
 and inflammation)
- RN 64-19-7 HCAPLUS
- CN Acetic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

The rest opens of the American Control of the Contr

$$_{\mathrm{HO}}$$
 $_{\mathrm{CH_{2}-CH_{2}-NH_{2}}}^{\mathrm{H}}$

RN 51-45-6 HCAPLUS CN 1H-Imidazole-4-ethanamine (9CI) (CA INDEX NAME)

$$CH_2-CH_2-NH_2$$

IT 127-09-3, Sodium acetate 631-61-8, Ammonium acetate
7365-45-9, HEPES 10377-48-7, Lithium sulfate
25322-68-3 92419-42-6
RL: ARU (Analytical role, unclassified); BUU (Biological use,
unclassified); ANST (Analytical study); BIOL (Biological study); USES
(Uses)
 (three-dimensional structures and models of Fc receptors for drug
 design for treating IgG-mediated tissue damage, hypersensitivity and
 inflammation)
RN 127-09-3 HCAPLUS
CN Acetic acid, sodium salt (7CI, 8CI, 9CI) (CA INDEX NAME)

Na

RN 631-61-8 HCAPLUS

CN Acetic acid, ammonium salt (8CI, 9CI) (CA INDEX NAME)

NH3

RN 7365-45-9 HCAPLUS

CN 1-Piperazineethanesulfonic acid, 4-(2-hydroxyethyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)

RN 10377-48-7 HCAPLUS

CN Sulfuric acid, dilithium salt (8CI, 9CI) (CA INDEX NAME)

2 Li

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)


$$HO - CH_2 - CH_2 - O - n$$

RN 92419-42-6 HCAPLUS

CN Platinum(2+), bis(1,2-ethanediamine-.kappa.N,.kappa.N')diiodo-, dinitrate (9CI) (CA INDEX NAME)

CM 1

CRN 92419-41-5 CMF C4 H16 I2 N4 Pt



CM · 2

CRN 14797-55-8 CMF N 03